No Data
No Data
Dezhan Healthcare (000813.SZ): Promote the pilot production and conversion of Simecraglutepeptide raw materials and recombinant human collagen raw materials as soon as possible.
Dezhan Healthcare (000813.SZ) stated at the investor relations event on September 23rd that in addition to the "Ale" and "Nile", the company will further explore the potential of its existing products, combine the approval of existing products with current policies and market conditions, and select products with market potential to resume production, such as warfarin sodium tablets and quetiapine hydrochloride tablets, enriching the company's pipeline of chemical drug products. In addition, efforts will be made to accelerate the conversion of income from early-stage research projects and promote the pilot production of Simvastatin raw materials and recombinant human collagen raw materials as soon as possible. Furthermore, the company currently has sufficient cash reserves and plans to achieve synergies through mergers and acquisitions.
Dezhan Healthcare (000813.SZ) affiliated company Dongfang Lue's collaborative research and development project for new indications has obtained clinical trial approval.
Dezhan Healthcare (000813.SZ) announced that the company recently received news that the company's joint venture company Peking Dongfang Lue Biomedical Science...
Dezhan Healthcare (000813.SZ): The joint venture company Dongfang Wuyue's new indications research and development project has obtained clinical trial approval.
Gelonghui September 22nd, dezhan healthcare (000813.SZ) announced that the company recently received a notification from its affiliated company Beijing Dongfang Lue Biomedical Technology Co., Ltd. (referred to as "Dongfang Lue" below). Dongfang Lue recently received the approval notice for clinical trials of drugs (No. 2024LP02122) issued by the National Medical Products Administration (NMPA), approving its collaborative research and development of the VGX-3100 project with the usa-based Inovio Pharmaceuticals, Inc. (referred to as "Inovio")
We Think That There Are Issues Underlying Dezhan Healthcare's (SZSE:000813) Earnings
Dezhan Healthcare (000813.SZ): First repurchased 0.23% of shares.
On September 3, 2024, dezhan healthcare (000813.SZ) announced that the company repurchased 5,026,200 shares of its own stock through a stock repurchase account for centralized bidding trading, accounting for 0.23% of the company's current total share capital. The highest fill price was 2.47 yuan/share, the lowest fill price was 2.44 yuan/share, and the total fill amount was 12,344,458.00 yuan (excluding transaction costs).
Dezhan Health: 2024 Semi-Annual Report Summary
No Data
No Data